Ac Clinical Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,142	1
2024	Research	$7,973	3
2023	Research	$80,855	9
2022	Research	$59,251	24
2021	Research	$93,647	26
2020	Research	$316,042	21
2019	Research	$68,526	15

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $267,018 20 payments
Exeltis, USA Inc. $235,254 56 payments
Bayer HealthCare Pharmaceuticals Inc. $124,684 13 payments
Pfizer Inc. $480 10 payments

Studies the money was for Research payments · program years 2019–2025

M16-837 $237,991 16 payments
BAY1454032 Essure System for Permanent Birth Control $115,569 9 payments
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $80,855 9 payments
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles $64,621 22 payments
Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability of LPRI-424, 13 Cycles $52,026 22 payments
A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles $30,528 1 payment
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome $29,026 4 payments
An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or laparoscopic tubal sterilization $7,973 3 payments
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females $7,225 2 payments
An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or lap $1,142 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.